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Abstract
Background: Chemotherapeutic drugs and newly developed therapeutic monoclonal antibodies are adequately delivered
to most solid and systemic tumors. However, drug delivery into primary brain tumors and metastases is impeded by the
blood-brain tumor barrier (BTB), significantly limiting drug use in brain cancer treatment.
Methodology/Principal Findings: We examined the effect of phosphodiesterase 5 (PDE5) inhibitors in nude mice on drug
delivery to intracranially implanted human lung and breast tumors as the most common primary tumors forming brain
metastases, and studied underlying mechanisms of drug transport. In vitro assays demonstrated that PDE5 inhibitors
enhanced the uptake of [
14C]dextran and trastuzumab (HerceptinH, a humanized monoclonal antibody against HER2/neu)
by cultured mouse brain endothelial cells (MBEC). The mechanism of drug delivery was examined using inhibitors for
caveolae-mediated endocytosis, macropinocytosis and coated pit/clathrin endocytosis. Inhibitor analysis strongly implicated
caveolae and macropinocytosis endocytic pathways involvement in the PDE5 inhibitor-enhanced Herceptin uptake by
MBEC. Oral administration of PDE5 inhibitor, vardenafil, to mice with HER2-positive intracranial lung tumors led to an
increased tumor permeability to high molecular weight [
14C]dextran (2.6-fold increase) and to Herceptin (2-fold increase).
Survival time of intracranial lung cancer-bearing mice treated with Herceptin in combination with vardenafil was
significantly increased as compared to the untreated, vardenafil- or Herceptin-treated mice (p,0.01). Log-rank survival
analysis of mice bearing HER2-positive intracranial breast tumor also showed a significant survival increase (p,0.02) in the
group treated with Herceptin plus vardenafil as compared to other groups. However, vardenafil did not exert any beneficial
effect on survival of mice bearing intracranial breast tumor with low HER2 expression and co-treated with Herceptin
(p.0.05).
Conclusions/Significance: These findings suggest that PDE5 inhibitors may effectively modulate BTB permeability, and
enhance delivery and therapeutic efficacy of monoclonal antibodies in hard-to-treat brain metastases from different primary
tumors that had metastasized to the brain.
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Introduction
Metastases of various tumors to the brain account for the
majority of brain cancers [1–3]. The prognosis for patients with
brain metastases remains poor with median survival of 4 to 5
months. Effective treatment of brain cancers is in part impeded by
a limited transport of anti-tumor therapeutics into the tumors
across brain tumor capillaries [4–6]. Although more permeable
than blood-brain barrier (BBB), this blood-brain tumor barrier
(BTB) largely prevents the delivery of non-lipid-permeable
chemotherapeutic drugs and monoclonal antibodies to the brain
resulting in lack of therapeutic benefit. Primary lung or breast
cancers are generally sensitive to therapeutic drugs, but their brain
metastases are not. For instance, patients with breast cancer
overexpressing HER2/neu proto-oncogene of the epidermal
growth factor receptor (EGFR) family who were treated with
trastuzumab/Herceptin (anti-HER2) have a high rate of brain
metastases [7,8]. It appears to be due to the inability of Herceptin
to penetrate BTB to control brain metastases, although it can
effectively control primary extracranial breast and lung tumors
[9–11]. The ability to temporarily increase BTB permeability
could dramatically enhance drug delivery to brain tumors,
potentially improving the efficacy and reducing side effects.
Therefore, understanding the biochemical modulation of BBB
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opening barriers for specific drug delivery to brain tumors.
Phosphodiesterase type 5 (PDE5) is a cGMP-specific phospho-
diesterase, which selectively inhibits cGMP degradation [12].
PDE5 inhibitors, sildenafil (ViagraH) and vardenafil (LevitraH), are
widely used, FDA-approved, oral medicines to treat erectile
dysfunction in men [13,14]. The cyclic guanosine monophosphate
(cGMP) is an important intracellular second messenger that has
been implicated in the regulation of vascular tone and permeabil-
ity [15]. Modulation of PDE activity, which can subsequently lead
to the intracellular cGMP accumulation, may result in increased
permeability of capillaries, including microvessels in brain tumors
[16]. Our previous publication showed that orally administered
vardenafil and sildenafil not only selectively increased BTB
permeability through KCa channel in gliosarcoma animal models,
but enhanced anti-tumor efficacy of a chemotherapeutic agent,
doxorubicin [17]. Here we sought to determine whether these
marketed PDE5 inhibitors could increase BTB permeability and
thereby improve the efficacy of monoclonal antibody treatment of




Mouse brain endothelial cells (MBEC), CRL-5904 cells (human
non-small cell lung cancer from a brain metastasis), BT-474 cells
(breast cancer cell line) and MDA-MB-435 (breast cancer cell line)
were obtained from the American Type Culture Collection
(ATCC, Manassas, VA), and were maintained in standard tissue
culture conditions. CRL-5904 and BT-474 tumor cell lines are
positive for HER2 expression, while MDA-MB-435 has low
HER2 expression [18].
Tumor Implantation
All animal studies were approved by Cedars-Sinai Medical
Center Institutional Animal Care and Usage Committee (IACUC)
and were conducted in strict accordance to the IACUC protocol
#2044.
The metastatic brain tumor xenograft models were established
using athymic nude mice (Charles River Laboratories Interna-
tional, Inc., Wilmington, MA). CRL-5904 cells (5610
4), BT-474
cells (1610
5) or MDA-MB-435 (5610
4)i n2 ml of 1.2%
methylcellulose/saline were implanted into the striatum respec-
tively with the coordinates of 2.3 mm lateral to bregma and
3.0 mm deep from dura. To establish breast metastatic brain
tumor model, estrogen pellets (Innovative Research of America,
Sarasota, FL) were implanted subcutaneously in nude mice one
week before intracranial tumor implantation.
In Vivo BTB Permeability Study
Fourteen days after tumor implantation, mice were treated with
vardenafil (LevitraH, GlaxoSmithKline, Research Triangle Park,
NC) at an oral dose of 10 mg/kg for 60 min for the maximal effect
[17], bradykinin (1.8 mg/kg; Sigma-Aldrich, St. Louis, MO) for
15 min [19,20], or saline as control. Mice were then subjected to
the regional permeability studies by tail vein injection of
radiotracer [
14C]dextran (molecular weight 70,000 D; 50 mCi/
kg; Sigma-Aldrich, St. Louis, MO). The method used to determine
the unilateral transport constant Ki (ml/g/min), the initial rate for
blood-to-brain transfer of radiotracer, has been described in our
previous publication with minor modification [17]. In brief, the Ki
was determined by radiotracer [
14C]dextran in the tumor core and
contralateral brain tissue using quantitative autoradiography
(QAR). Quantitative analysis of the regional radioactivity was
performed using ImageJ software (National Institutes of Health,
Bethesda, MD).
Herceptin-Alexa Fluor 680 Uptake in Metastatic Brain
Tumor Model
Trastuzumab (HerceptinH, Genentech, Inc., San Francisco, CA)
was labeled with an Alexa FluorH680 fluorescent dye (Invitrogen,
Carlsbad, CA) using Xenofluor labeling kit (Caliper, Alameda,
CA). Tumor-bearing mice were treated with oral vardenafil
(10 mg/kg) or saline as control, and then mice were subjected to
the permeability studies by tail vein injection of 5 mg/kg
Herceptin-Alexa Fluor 680. Xenogen IVIS 200 whole animal
fluorescent imager (Caliper Life Sciences, Hopkinton, MA) was
used for assessment of drug distribution and localization in
isoflurane-anesthetized nude mice at different time points (before
drug administration; 1 h, 3 h, 6 h after drug administration). Six
hours after drug administration, mice were anesthetized with i.p.
ketamine and xylazine and subjected to transcardial perfusion to
eliminate the circulating drug in blood vessels. The brains were
harvested to detect the fluorescent signal. Signal intensities in the
tumor were analyzed by Xenogen Living ImageH, Version 2.50
(Caliper Life Sciences, Hopkinton, MA). The brains were snap-
frozen in liquid nitrogen and sectioned on a cryostat (Leica
Microsystems, Mannheim, Germany). Herceptin-Alexa Fluor 680
accumulation in the tumor cells was further studied by confocal
microscopy using Leica confocal laser scanning microscope TCS
SP5 (Leica Microsystems, Germany).
Survival Study in Brain Metastasis Models: Lung and
Breast Cancers
For the survival experiments, CRL-5904, BT-474 or MDA-
MB-435 tumor-bearing mice were randomly divided into four
groups treated as follows: (1) control saline; (2) vardenafil (10 mg/
kg, orally, five times per week; dose was based on previous data
[17]); (3) Herceptin (10 mg/kg, intravenously via tail vein, twice
per week; dose was based on our preliminary data and a previous
publication [21]; and (4) Herceptin (10 mg/kg, intravenously,
twice per week) plus vardenafil (10 mg/kg, orally, five times per
week). Mice received their treatments beginning at day 4 after
tumor implantation. CRL-5904 cell implantation and survival
experiment was repeated two times with six animals per group.
The survival data were very similar and were thus combined
together. BT-474 cell line is growing longer and the experiment
duration is estimated at about three months. This experiment was
performed once with a higher number of animals per group, n=8.
MDA-MB-435 tumor-bearing survival study had 5 to 8 mice per
group. Mice were monitored carefully for clinical signs attributable
to brain tumor growth or until death. The efficacy of therapy was
estimated by the median survival time of the animals.
Western Blot Analysis of Apoptotic Effect on Brain Tissues
of Treated Mice
Normal and tumor mice brain tissues were collected after
treatment with saline, vardenafil, Herceptin, and Herceptin plus
vardenafil. Samples from five tumors in each group were pooled.
Total protein was extracted and concentrations were determined
using a BCA assay kit (Bio-Rad Laboratories, Hercules, CA).
Equal amounts of protein were loaded on 10% SDS-polyacryl-
amide gel and transferred to nitrocellulose membranes. For
apoptosis detection, the membranes were probed with primary
antibodies to cleaved Poly-ADP-Ribose-Polymerase (PARP), an
89-kDa PARP fragment that is considered as a marker of
Levitra in Brain Drug Delivery
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dehydrogenase (GAPDH; BD Pharmingen, San Diego, CA),
respectively. Horseradish peroxidase-conjugated secondary anti-
bodies were used for detection followed by enhanced chemilumi-
nescence development (Bio-Rad Laboratories, Hercules, CA).
In Vitro BBB Permeability Model
To mimic BBB condition in vitro, transwell system (Corning,
Inc., Corning, NY) was used for cellular drug transport study.
MBEC were seeded into the inserts of transwell system at 2610
4/
well and cultured for 2 to 3 days until confluence. Washed cells
were incubated at 37uC for 30 min in culture media without
serum as control or in media with 10 mg/ml vardenafil. Then,
these media were removed and replaced with [
14C]dextran at
0.2 mCi/ml in the inserts. After 5 or 30 min incubation, the media
from the low chambers were collected and subjected to
radioactivity measuring by liquid scintillation counting using a
Beckman LS 6000 Scintillation Counter (Beckman Coulter,
Fullerton, CA). Triplicate wells were run for each group.
Drug Uptake by Endothelial Cells
The same numbers of MBEC (2610
4/well) were seeded in flat
bottom 96-well plates and cultured until confluence. To verify
which endocytosis pathways were involved in PDE5 inhibitor-
induced drug uptake, several inhibitors were examined by first
incubating cultured MBEC for 30 min in serum-free medium as
follows: Filipin (1 to 5 mg/ml) and methyl-b-cyclodextrin (2.5 to
10 mM) to inhibit caveolae-mediated endocytosis; amiloride (25 to
50 mm) to inhibit macropinocytosis; chlorpromazine (2.5 to 10 mg/
ml) and phenylarsine oxide (7.5 to 30 mM) to inhibit coated pit/
clathrin endocytosis pathway [22,23]. All inhibitors were pur-
chased from Sigma-Aldrich (St. Louis, MO). The medium was
replaced with the one containing pathway inhibitors and PDE5
inhibitors (50 mg/ml sildenafil, ViagraH, Pfizer, NY; or 10 mg/ml
vardenafil), and cells were incubated at 37uC for 30 min. Then the
medium was removed and replaced with Herceptin-Alexa Fluor
680 (25 mg/ml) for 0.5 or 3 hrs. After washing, cells were lysed in
100 ml of 1% (w/v) Triton X-100. Two repeats of this experiment
were run, with similar results. Uptake data are expressed as
percent of control. Uptake of labeled Herceptin in cultures without
endocytosis inhibitors was also tested. A standard curve was
obtained in untreated cells using different dilutions of Herceptin-
Alexa Fluor 680 in lysis buffer. Fluorescent signals were measured
using excitation at 680 nm and emission at 720 nm in a
microplate reader (Molecular Devices, Sunnyvale, CA). Triplicate
wells were run for each group. Data are expressed as mg Herceptin
per one ml of lysis buffer.
Herceptin-Alexa Fluor 680 Uptake by Cultured MBEC
MBEC were seeded in Lab-Tek
TM chamber slides (Thermo
Fisher Scientific, Rochester, NY). Washed cells were pretreated
with filipin (5 mg/ml) for 30 min in serum-free media followed by
incubation at 37uC for 30 min in culture media as control or
media with a PDE 5 inhibitor (10 mg/ml vardenafil). Then, this
medium was removed and replaced with the one containing
Herceptin-Alexa Fluor 680 (25 mg/ml) for 3 hrs. Cells were
washed with PBS, fixed with 4% paraformaldehyde for 20 min,
and incubated with anti-caveolin-1 (1:100; BD Biosciences, San
Jose, CA) antibodies at 4uC overnight. The signals were detected
with Texas Red-conjugated secondary antibodies (1:200; Jackson
ImmunoResearch, West Grove, PA). To detect HER2 expression
on cells, they were stained with anti-HER2 (1:100; Upstate,
Temecula, CA) by indirect immunofluorescence. The cells were
counterstained with 49, 6-diamidino-2-phenylindole (DAPI; Vec-
tor Laboratories, Burlingame, CA) and cover-slipped. The slides
were examined under a Leica confocal microscope. Negative
control experiments included omission of primary antibodies and
were routinely performed.
Statistics
Statistical analyses were performed using the Student’s t-test
(Prism4, GraphPad Software, San Diego, CA). Animal survival
was analyzed by the Kaplan-Meier method (log-rank test). Data
were expressed as mean 6 standard error of mean (SEM). p,0.05
was considered significant.
Results
Vardenafil Effects on Cell Membrane Permeability in Vitro
and in Vivo
In the in vitro setting, a Corning transwell system was used for
cellular drug transport study as a model of BBB. Mouse brain
endothelial cells were seeded into the transwell inserts for the
examination of transcytosis of [
14C]dextran (MW 70,000 D this
molecular weight was selected to compare with big molecular
drugs, therapeutic monoclonal antibody in our case). At different
intervals after dextran addition, the medium in the low chamber
was collected to detect the transported dextran by liquid
scintillation counting. The results showed that vardenafil
significantly increased the transcytosis of [
14C]dextran through
MBEC compared to medium-treated cells (Figure 1a) both at
5 min (110.6767.37 vs. 70.6763.06 cpm; p,0.01) and 30 min
(136.3364.54 vs. 64.00610.58 cpm; p,0.01).
In the in vivo study, vardenafil (n=5) was given at an oral dose of
10 mg/kg for the maximal effect according to previous publication
[17]. Its effects on the initial blood to brain or blood to tumor
transport, Ki, were studied and compared with that of bradykinin
(positive control), which increases BTB transport [17,24], after
infusing with a radiotracer-high molecular weight [
14C]dextran.
Vardenafil treatment resulted in a 2.6-fold increase in BTB
permeability (38.49614.23 nCi/g vs. 15.0966.09 nCi/g in saline-
treated controls; p,0.01). Consistent with previous publications
[17,24], administration of bradykinin (1.8 mg/kg, n=6) similarly
increased the Ki in the brain tumors (40.06611.13 vs.
15.0966.09 nCi/g; p,0.01) as compared to the saline-treated
controls (n=5). Transport of [
14C]dextran in normal brain was
not affected by the treatments (Figure 1b).
To examine in vitro uptake of Herceptin-Alexa Fluor 680,
endothelial cells were incubated with labeled drug with or without
preincubation with vardenafil. Vardenafil-treated MBEC showed
significantly increased Herceptin-Alexa Fluor 680 uptake
(Figure 2a) compared to medium only control (1.1960.03
vs. 0.6560.07 mg/ml, p,0.01 at 30 min; 1.7960.07 vs.
0.9560.05 mg/ml, p,0.01 at 3 hrs). It should be noted that
MBEC did not express surface HER2 in contrast to CRL-5904
and BT-474 HER2-postive tumor cell lines used (Figure 2b).
Mechanisms of Antibody Delivery Through Endothelial
System in Vitro
To explore the underlying mechanisms of PDE5 inhibitors-
induced BTB permeability increase, we have examined the role of
three major pathways for substance endocytosis, such as clathrin-
and caveolae-mediated transport, as well as macropinocytosis. We
further investigated whether increased transport induced by PDE5
inhibitors was associated with any of these major mechanisms
(Figures 3, 4). Caveolae-mediated endocytosis was inhibited by
filipin and methyl-b-cyclodextrin [22,23]. The vardenafil- or
sildenafil- enhanced uptake of Herceptin-Alexa Fluor 680 was
Levitra in Brain Drug Delivery
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methyl-b-cyclodextrin (Figure 3 a, b; left and middle graphs;
Figure 4, p,0.001 vs. vardenafil/sildenafil-stimulated control).
Because vardenafil and sildenafil increased Herceptin uptake in
vitro about two-fold (Figure 2a), caveolae pathway inhibitors agents
essentially brought Herceptin uptake down to control levels
without PDE5 inhibitors. Next, we examined the role of
macropinocytosis by using its inhibitor, amiloride [22,25]. The
uptake of Herceptin-Alexa Fluor 680 increased by vardenafil or
sildenafil was also similarly inhibited by amiloride pretreatment
(Figure 3 a, b; right graphs; Figure 4; p,0.001 vs. vardenafil/
sildenafil-stimulated control). However, clathrin pathway inhibi-
tors, chlorpromazine and phenylarsine oxide, did not significantly
interfere with the effects of vardenafil or sildenafil (Figure 3 c, d;
Figure 4; p.0.05 vs. vardenafil/sildenafil-stimulated control),
possibly due to lack of HER2 receptor expression on MBEC
(Figure 2b). Therefore, stimulation of caveolae and macropinocy-
tosis pathways may play a major role in PDE5 inhibitor effect on
Herceptin uptake.
To further examine the effect of PDE5 inhibitors on drug
uptake, we detected Herceptin-Alexa Fluor 680 in cultured MBEC
using confocal microscopy. Caveolae expression was monitored by
Figure 1. PDE5 inhibitor, vardenafil, increases permeability in an in vitro BBB model and in metastatic brain tumors in mice. (a)
Vardenafil significantly increases the uptake of [
14C]dextran (MW 70,000 D) by MBEC compared to medium treated-cells at 5 min (p,0.01) and 30
minutes (p,0.01) respectively in an in vitro BBB model. (b) Effects of oral PDE5 inhibitor on the rate of radioactive dextran transport, Ki, into the
metastatic brain tumors. Vardenafil (10 mg/kg) was administered orally followed by permeability determination as in a previous publication [17].
Intravenous administration of short-term vascular modulator, bradykinin (1.8 mg/kg) served as a positive control [31,43]. Oral administration of
vardenafil (n=5) significantly increases Ki in the tumor center compared with saline control (n=5). Intravenous infusion of bradykinin (n=6) also
significantly increases Ki in the tumor core compared with control. No permeability increase in the contralateral normal brains. **, p,0.01.
doi:10.1371/journal.pone.0010108.g001
Figure 2. PDE5 inhibitor induces permeability increase of therapeutic antibody, Herceptin. (a) PDE5 inhibitor vardenafil significantly
increases Herceptin-Alexa Fluor 680 uptake by cultured MBEC compared to medium treated-cells at 0.5 and 3 hrs (close to 2-fold; vardenafil vs.
control). **, p,0.01. (b) HER2 expression on different cell lines. BT-474 breast cells have the highest HER2 expression, followed by CRL-5904 cells.
HER2 expression on MBEC is not detected. Lack of HER2 on MBEC suggests that Herceptin could not be internalized by receptor-mediated clathrin-
dependent endocytosis and may account for absence of effect observed with the corresponding inhibitors, chlorpromazine and phenylarsine oxide
(Figure 4). Nuclei are counterstained with DAPI. Scale bar =25 mm.
doi:10.1371/journal.pone.0010108.g002
Levitra in Brain Drug Delivery
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With vardenafil pretreatment, Herceptin-Alexa Fluor 680 uptake
by MBEC was higher compared with Herceptin alone and filipin-
pretreated cells; the latter two were similar to each other (Figure 5).
Filipin (Figure 5), methyl-b-cyclodextrin, and amiloride (data not
shown here) all blocked the PDE5 inhibitor-induced increase in
Herceptin uptake, suggesting that the effects of PDE5 inhibitors
are due to the activation of caveolae-mediated endocytosis or
macropinocytosis.
Effect of PDE5 Inhibitors on Herceptin Uptake by
Metastatic Brain Tumors
The in vitro data prompted us to test whether PDE5 inhibition
could also increase therapeutic antibody uptake by the metastatic
brain-implanted tumors. We chose Herceptin because it is a FDA-
approved humanized monoclonal antibody to treat HER2-positive
tumors. It also has limited access across BBB/BTB [9,26].
Herceptin was labeled with Alexa Fluor 680 fluorescent dye for
detection by Xenogen IVIS 200 imaging system. Oral adminis-
Figure 3. Examination of the involvement of major endocytic pathways in PDE5 inhibitors-induced permeability increase. Each
inhibitor was tested in different dosages and at two incubation time points (0.5 and 3 hrs). (a, b; left graphs) Filipin, a caveolae pathway
inhibitor, suppresses the effect of vardenafil (50.1612.4% inhibition) and sildenafil (52.766.3% inhibition) on cultured MBEC at different
concentrations (1.25, 2.5, and 5 mg/ml). (a, b; middle graphs) Methyl-b-cyclodextrin, another caveolae pathway inhibitor, has the same
concentration-dependent (2.5 to 10 mM) inhibition on vardenafil (51.1610.0% inhibition) and sildenafil (60.061.7% inhibition) effects.
( a ,b ;r i g h tg r a p h s )A m i l o r i d e ,am a cropinocytosis inhibitor, blocks the effect of vardenafil (58.863.6% inhibition) and sildenafil
(49.168.2% inhibition) at concentrations of 25 and 50 mM. (c, d; left graphs) Chlorpromazine (2.5, 5.0, and 10 mg/ml), a clathrin pathway
inhibitor, does not significantly reduce the effect of vardenafil (27.069.8% inhibition) or sildenafil (18.863.8% inhibition) on cultured MBEC.
( c ,d ;r i g h tg r a p h s )P h e n y l a r s i n eo x i d e( 7 . 5 ,1 5 ,a n d3 0m M ) ,a n o t h e rc l a t hrin pathway inhibitor, equally doesn’t block the effect of vardenafil
(16.0613.1% inhibition) or sildenafil (12.967.0% inhibition) on cultured cells. Data in parentheses are expressed as inhibition at high dose
(mean 6 SEM).
doi:10.1371/journal.pone.0010108.g003
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increase of Herceptin-Alexa Fluor 680 transport in brain tumor
compared with saline treated-mice (Figure 6 a-c; n=5; p,0.05).
Herceptin-Alexa Fluor 680 signal was not detected in the
contralateral normal brains (Figure 6a, b). The accumulation of
Herceptin was further observed on brain tumor cryostat sections
by confocal microscopy. Sections of vardenafil-treated tumors had
markedly higher drug accumulation compared with Herceptin
alone (Figure 6d) or saline-treated controls. No fluorescence signal
was detected in the contralateral normal brain tissue.
Treatment of Lung and Breast Intracranial Tumors
To determine if the permeability increase in metastatic brain
tumors by the PDE5 inhibitors can be translated into improved
efficacy of tumor therapy, Herceptin was administered to mice
with brain-implanted lung metastatic CRL-5904 and breast
cancer BT-474 tumors positive for HER2/neu. CRL-5904 bearing
mice were treated with Herceptin (10 mg/kg, twice per week,
intravenously) [21] beginning at day 4 after tumor implantation,
with oral administration of vardenafil (10 mg/kg, 5 times per
week). Log-rank analysis of the Kaplan–Meier survival curves
showed a significant increase (p,0.01) in survival of mice treated
with Herceptin plus vardenafil as compared to the saline-treated,
vardenafil alone- or Herceptin alone-treated mice (Figure 7a). The
mean survival time for mice treated with Herceptin plus vardenafil
combination increased by about 30% and was significantly longer
(3568 days) compared to those of saline- (2262 days), Herceptin
alone- (2562 days), and vardenafil alone-treated mice (2562
days). In mice bearing intracranial BT-474 breast tumors, log-rank
analysis of the Kaplan–Meier survival curves also showed a
significant survival increase (p,0.02) in the group treated with
Herceptin plus vardenafil as compared to the saline-treated,
Herceptin alone- or vardenafil alone-treated mice (Figure 7b). The
mean survival time for mice treated with Herceptin plus vardenafil
was significantly longer (72618 days) compared to those of saline-
(5767 days), Herceptin alone- (5969 days), and vardenafil alone-
treated mice (50611 days). Survival with Herceptin plus
vardenafil was thus about 20% longer than with Herceptin alone.
However, there was no beneficial effect of vardenafil on Herceptin
treatment of mice bearing low HER2 expressing MDA-MB-435
tumor (p.0.05; Figure 7c).
Herceptin binds to the extracellular domain of HER2 and
inhibits proliferation and survival of HER2-dependent tumors by
promoting DNA fragmentation associated with apoptotic cell
death [27]. In addition to monitoring survival, we also detected the
apoptotic effect on the brain tissue after the treatments. The brain
tumor tissues and contralateral normal brain tissues were
collected, pooled at five per group, and subjected to apoptotic
assay by Western blot for cleaved 89-kDa fragment of poly-ADP-
ribose-polymerase (PARP) as a marker of apoptosis. CRL-5904
brain tumors treated by Herceptin plus vardenafil showed about
two-fold higher level of cleaved PARP compared with untreated,
vardenafil alone- or Herceptin alone-treated brain tumors
(Figure 8a, top). The ratio of cleaved PARP relative to
housekeeping protein GAPDH showed marked increase in the
Herceptin plus vardenafil group compared to all other groups
(Figure 8b). We did not detect any cleaved PARP in the
contralateral normal brain tissues with different treatments
(Figure 8a, bottom). The enhanced apoptosis in the Herceptin
plus vardenafil treated brain tumor tissue indicated that vardenafil
Figure 4. Effect of inhibitors of three major endocytic pathways on reversing vardenafil and sildenafil enhancement of Herceptin
uptake. Bar graph represents high dosage results in Fig. 3, averaged for both 0.5 and 3 hrs of incubation (mean 6 SEM). Control, Herceptin uptake
by cells incubated with PDE5 inhibitors (data on vardenafil and sildenafil were similar, so they were combined and taken as 100%). Both inhibitors of
caveolae endocytic pathway (filipin and methyl-b-cyclodextrin) significantly reduced PDE5 inhibitor effect compared to vardenafil/sildenafil-
stimulated control, bringing Herceptin uptake to baseline level. The same was true for macropinocytosis inhibitor, amiloride. The effect of either
inhibitor of coated pit/clathrin pathway (chlorpromazine or phenylarsine oxide) on Herceptin uptake was non-significant (N.S.). V, vardenafil; S,
sildenafil; MPC, macropinocytosis. ***, p,0.001.
doi:10.1371/journal.pone.0010108.g004
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BT-474 tumors we did not detect a significant increase in cleaved
PARP in vardenafil plus Herceptin treatment compared with
other groups, maybe due to the longer survival time (up to 3
months) in this animal model.
Discussion
In this study, we sought to determine whether cGMP-specific
PDE5 inhibitors could increase the rate of delivery of large
macromolecular drugs exemplified by therapeutic antibodies
across the BTB in order to improve efficacy of drug therapy for
metastatic brain tumors. We have also examined possible
mechanisms underlying PDE5 inhibitor action, related to changes
in vesicular transport. It is shown here that oral administration of
PDE5 inhibitor vardenafil selectively increased the rate of brain
tumor accumulation of intravenously administered [
14C] high
molecular weight dextran and a monoclonal antibody trastuzu-
mab/Herceptin against HER/neu. Importantly, Herceptin in
combination with vardenafil significantly improved the survival
of metastatic brain tumor-bearing mice with increased tumor
apoptosis. Inhibitors of caveolae endocytosis and macropinocytosis
pathway could block PDE5 inhibitor-induced Herceptin uptake by
cultured mouse brain endothelial cells, suggesting that stimulation
of these pathways was a likely mechanism of PDE5 inhibitor
action. Collectively, these findings suggest that PDE5 may serve as
an effective target for pharmacological modulation of BTB
permeability to enhance delivery and therapeutic effect of
otherwise inefficient drugs in the metastatic brain tumors.
Vardenafil and sildenafil are oral drugs that are currently used
to treat erectile dysfunction in men. They selectively inhibit the
activity of cGMP-specific PDE5, and subsequently increase the
cGMP level [12]. Our previous study showed that oral
administration of vardenafil and sildenafil selectively increased
BTB permeability (1.8-fold and 2.7-fold, respectively) compared
with control groups. Transport across the BTB into tumor tissues
reached the maximum at 60 to 75 min after administration of
sildenafil and vardenafil [17]. In the present study, we chose the
optimal dose of vardenafil at 10 mg/kg to treat metastatic brain
tumor-bearing mice. Orally administered vardenafil selectively
increased permeability of metastatic brain tumors, but not the
contralateral normal brain to high molecular weight [
14C]
dextran. Bradykinin that is known to transiently open up BTB
was included in this study as a positive control. As expected,
bradykinin resulted in a significant increase in BTB permeability,
which is consistent with our previous observations [16,28,29].
However, bradykinin has a short half-life [30], and its effect on
transport into tumors is diminished within 15–20 min after
Figure 5. Co-localization of Herceptin-Alexa Fluor 680 with caveolae in cultured MBEC. Cultured cells have low uptake of Herceptin (Her),
which is markedly increased when co-administered with vardenafil (Var). Note pronounced co-localization of Herceptin with caveolin-1. The
enhancing effect of vardenafil is virtually abolished by filipin (Fil). Vardenafil was used at 10 mg/ml. Nuclei were counterstained with DAPI. Scale bar
=25mm.
doi:10.1371/journal.pone.0010108.g005
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animal model. Vardenafil was administered orally at 10 mg/kg followed by tail vein injection of Herceptin-Alexa Fluor 680. (a) Brain tumors treated
with Herceptin and vardenafil; (b) Brain tumors treated with Herceptin and saline; fluorescence signals were detected by Xenogen IVIS 200 imaging.
(c) Quantitation of Herceptin accumulation in the tumor. Oral administration of vardenafil (n=5) significantly increased Herceptin uptake by the brain
tumors compared with saline control (n=5). * p,0.05. (d). Herceptin uptake and accumulation in the metastatic brain tumor tissue. Sections of a
tumor after Herceptin plus vardenafil treatment have markedly brighter fluorescence with significantly more positive cells compared with saline-
treated control. No fluorescence signal was detected in the contralateral normal brain tissue. Nuclei were counterstained with DAPI. Scale bar
=50mm.
doi:10.1371/journal.pone.0010108.g006
Figure 7. Effect of vardenafil on Herceptin therapy in metastatic brain tumor-bearing mice. (a) Effect of vardenafil on the survival rates of
CRL-5904 metastatic brain tumor-bearing mice. Groups of mice (control, n=12; Herceptin, n=10; vardenafil, n=10; Herceptin + vardenafil, n=12)
were treated with saline, Herceptin (10 mg/kg, i.v.), vardenafil (10 mg/kg, oral), or Herceptin (10 mg/kg, i.v.) plus vardenafil (10 mg/kg, oral). All mice
were treated starting on the fourth day after tumor implantation. The Kaplan–Meier survival curves showed that mice treated with Herceptin plus
vardenafil survived significantly longer than any other of the three groups of mice (p,0.01). (b) Effect of vardenafil on Herceptin therapy in BT-474
(breast cancer) metastatic brain tumor-bearing mice. Groups of mice (control, n=8; vardenafil, n=6; Herceptin, n=8; Herceptin + vardenafil, n=7)
were treated with saline, Herceptin, vardenafil, or Herceptin plus vardenafil in the same way as CRL-5904 tumor-bearing animals. The Kaplan–Meier
survival curves again showed that mice treated with Herceptin plus vardenafil survived significantly (p,0.02) longer than any other of three groups
of mice. (c) Effect of vardenafil on Herceptin therapy in MDA-MB-435 (breast cancer with low HER2 expression) metastatic brain tumor-bearing mice.
Groups of mice (control, n=8; vardenafil, n=5; Herceptin, n=5; Herceptin + vardenafil, n=8) were treated with saline, vardenafil, Herceptin, or
Herceptin plus vardenafil in the same way as mentioned above. The Kaplan–Meier survival curves showed that there was no significant difference
among the treatment groups (p.0.05).
doi:10.1371/journal.pone.0010108.g007
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difficult. Vardenafil was found to be not only as effective as
bradykinin in increasing drug transport into brain tumors, but to
also extend the BTB opening up to 105 min, which would give a
serious advantage for delivering therapeutics into brain tumors in
clinic [17].
Two major cellular mechanisms have been suggested to account
for increased BTB permeability: vesicular transcellular transport
and tight junction-controlled paracellular permeability of endo-
thelial cells [32–34]. Our previous studies indicated that increased
vesicular transport was an important mechanism for enhanced
drug delivery via biochemical modulation of BTB [19,34,35]. We
also showed that vardenafil treatment did not significantly affect
tight junction integrity in tumor capillary endothelium [17]. These
data suggested that tight junction-controlled paracellular mecha-
nism might not play a key role in the BTB permeability increase
by vardenafil. Therefore, we have examined the role of three
major pathways for substance endocytosis, including coated pit/
clathrin- and caveolae-mediated transport, as well as macropino-
cytosis, as possible mediators of vardenafil action. Our data
demonstrate that inhibitors of caveolae or macropinocytosis could
abolish PDE5 inhibitor-induced Herceptin-AlexaFluor-680 uptake
in cultured MBEC, suggesting the involvement of these pathways
in vardenafil effects. Although many molecules are preferentially
internalized by one major endocytic pathway [36], it is not
uncommon for certain molecules to use several endocytic
pathways at the same time [37]. Moreover, PDE5 inhibitors
enhance BTB permeability through increasing the cGMP level
[12,17]. It was also reported that the vascular smooth muscle
relaxation induced by cGMP was impaired in the presence of
methyl-b-cyclodextrin, a caveolae pathway inhibitor [38], further
supporting the role of caveolae pathway in PDE5 inhibitor-
induced BTB permeability increase. Caveolae are most abundant
in continuous capillary endothelia [39] and could be a suitable
means for the transfer of anti-cancer drugs or other therapeutics
from blood to brain [40]. Receptor (clathrin)-mediated endocytosis
mechanism of Herceptin delivery did not appear to play an
important role, possibly due to lack of HER2 receptor expression
on MBEC.
Herceptin is a humanized monoclonal antibody for treatment of
patients with primary breast, non-small lung or prostate cancers
that overexpress HER2. Herceptin minimally crosses the BBB/
BTB [9], which may be a reason for lack of Herceptin efficiency in
treating tumor metastases to the brain/central nervous system
[2,6,41]. In this study, we showed that oral administration of
vardenafil increased Herceptin delivery to metastatic brain tumors
through BTB, but not through BBB to contralateral brain tissue.
This resulted in a specific accumulation of the antibody in the
brain tumor but not in the normal brain, apparently leading to
enhanced anti-tumor effect of Herceptin and increased survival of
treated mice with HER2-positive lung and breast cancers
implanted into the brain as a model of metastasis. This beneficial
effect on animal survival was clearly related to Herceptin action
because it was not observed in low HER2 expressing tumors. The
HER2-positive brain tumors treated with Herceptin plus varde-
nafil showed significantly higher level of cleaved PARP (apoptotic
marker) compared with other treatment groups, consistent with
known proapoptotic mechanism of Herceptin action [27].
Taken together, the presented data demonstrate that oral
administration of PDE5 inhibitors selectively increases transport
across brain tumor capillaries and significantly enhances the anti-
tumor effect of Herceptin in mouse models of metastatic HER2/
neu-positive brain tumors. The results suggest that PDE5 inhibitors
may exert their effect through stimulating caveolae-mediated
endocytosis and macropinocytosis.
Because lung and breast cancers are the most common primary
tumors for brain metastases, treating brain metastases with
clinically feasible strategies may have an important effect on
disease outcome. Our data suggest that, for metastatic brain
tumors positive for EGF family receptors, such as HER2 or
EGFR, PDE5 inhibitors may offer a possibility of efficacious
treatment using pertinent antibodies (trastuzumab and cetuximab,
respectively) that are otherwise inefficient. Potentially, they could
also be applied together with CD20 antibody rituximab to treat
brain metastases of lymphoma. Because PDE5 inhibitors seem to
increase BTB permeability to high molecular weight drugs, they
might enhance brain tumor accumulation and thus, therapeutic
efficacy of other classes of drugs including emerging nanomedi-
cines [42]. This strategy to circumvent the BBB/BTB may
significantly expand the treatment options for patients with brain
metastases.
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